The replay of the webcast will be accessible for 90 days. Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders.
HC Wainwright reissued their buy rating on shares of Bright Minds Biosciences (NASDAQ:DRUG – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports.
Chief Medical Officer of Bright Minds Biosciences. “We are fortunate to welcome these accomplished and highly respected researchers to the Bright Minds team at this exciting juncture.
Please note that Sector and Industry values may differ from other sources, as no adjustments have been made. Bright Minds Biosciences Inc's Revenue of - ranks in the - percentile for the Sector. The ...
NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company ...
Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug development and research ...
The replay of the webcast will be accessible for 90 days. Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback